Evidence map›Paper›PMID 37808694›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Germline mutations and developmental mosaicism underlying

Risa Burr, Ignaty Leshchiner, Christina L Costantino, Martin Blohmer, Tilak Sundaresan, Justin Cha, Karsen Seeger, Sara Guay, Brian P Danysh, Ira Gore and 16 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 1 country.

Risa BurrMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Ignaty LeshchinerCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Christina L CostantinoMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Martin BlohmerCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Tilak SundaresanMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Justin ChaCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Karsen SeegerMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Sara GuayMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Brian P DanyshCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Ira GoreSt Vincent's Hospital, Birmingham, AL, USA.
Raquel A JacobsCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Kara SlowikCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Filippo UtroIBM Research, Yorktown Heights, NY, USA.
Kahn RhrissorrakraiIBM Research, Yorktown Heights, NY, USA.
Chaya LevovitzIBM Research, Yorktown Heights, NY, USA.
Jaimie L BarthDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Taronish DubashMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Brian ChirnMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Laxmi ParidaIBM Research, Yorktown Heights, NY, USA.
Lecia V SequistMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Jochen K LennerzDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Shyamala MaheswaranMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Kamila NaxerovaCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Gad GetzMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Daniel A HaberMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Harvard University · USBroad Institute · USMassachusetts General Hospital · USIBM (United States) · USHoward Hughes Medical Institute · USSt. Vincent's Birmingham · US

Funding

Project 3P50CA265826 · NCI · DANA-FARBER CANCER INST · PI Daniel Botelho Costa · 2022 to 2026
$13.7M
The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted TherapiesR01CA137008 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Aaron N Hata, ZOFIA PIOTROWSKA · 2009 to 2026
$5.7M
Illuminating the evolutionary history of colorectal cancer metastasis: basic principles and clinical applicationsR37CA225655 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAXEROVA, KAMILA · 2018 to 2024
$3.0M
NCI NIH HHS P50 CA265826NCI NIH HHS R01 CA137008NCI NIH HHS R37 CA225655
6 · The paper itself

Abstract

While the development of multiple primary tumors in smokers with lung cancer can be attributed to carcinogen-induced field cancerization, the occurrence of multiple primary tumors in individuals with

Identifiers

PMID37808694
PMCPMC10557804
OpenAlexW4387164093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.